u/zeynep_weiss

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

the interesting data is the combination, not the monotherapy

Correcting myself upthread: I gave the 4-week figure and the paper reports 50 weeks.

This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.

interval stretching is the most commonly described approach here

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

private pricing varies enormously between neighbouring countries

Careful — anything touching pregnancy is not a board question in any form.

What is prompting the decision — cost, supply, side effects, or something else?

That is preclinical work and the thread is treating it as a human finding.

Small fix — that is the New Zealand arrangement, and the question is about Australia.

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

decide what you are watching for before you stop

Have you had the conversation with a clinician yet?

do not chase somebody else’s titration schedule, they are not you

2.4 is a ceiling, not a target

REDEFINE is the combination programme

That trial did not enrol the population you are asking about, so it cannot answer this.

Not convinced. You changed the dose and the week at the same time, so you cannot attribute the change to either.

Right, and the habits from the losing phase are the part that has to outlive the dose.

What did the pharmacy quote for the private price?

Kept the script and the receipt for a private health claim and both were requested.

Small correction: 2.4mg is the maintenance ceiling on the label, not the starting maintenance dose. The distinction matters for anyone reading this later.

What are you planning to watch for, and over what period?

Disagreeing with this bit: stretching and reducing are different things and the post treats them as one.

stretching to ten days then twelve is the pattern people report

Apotheke pricing and pharmacy pricing elsewhere are different systems

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it.

Agreed — and the exposure lag means the first fortnight tells you almost nothing.

Disagree — that is a general claim about absorption and the specific question needs a pharmacist rather than a board.

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

the language barrier is a real cost and nobody budgets for it

Not convinced by the attribution. That pattern tracks the cycle in your own log more closely than it tracks the dose.

independent purity data on this compound is thin

say which country or the thread is useless

Not convinced. You changed the dose and the week at the same time, so you cannot attribute the change to either.